ReviewCureus2025
Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Complications: A Systematic Review of Microbial Patterns, Incidence, Risk Factors, and Management Strategies in Contemporary Practice.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Laparoscopic transcystic common bile duct exploration via a cystic duct remnant for post-cholecystectomy residual choledocholithiasis: a case report.Journal of surgical case reports · 2026Article
- Risk factors for post-ERCP pancreatitis: a retrospective analysis of nursing-related factors.BMC surgery · 2026Article
- Determinants and Frequency of Acute Kidney Injury After Endoscopic Retrograde Cholangiopancreatography.Cureus · 2026Article
- Anaesthetic Adverse Events During Propofol-Based Sedation for ERCP: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Microbial dysbiosis in cholangiocarcinoma.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is a critical therapeutic intervention for hepatobiliary and pancreatic disorders, yet it carries significant morbidity and mortality risks due to the complications that may occur due to changes in the microbiota of the hepatobiliary system. Achieving the best patient results requires mastery of current complications, their risk factors, and proven management methods. This study aims to systematically review the incidence, risk factors, microbial patterns, and management strategies of post-ERCP complications in contemporary practice. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Multiple databases were searched for studies published between 2004 and 2025 reporting post-ERCP complications. Studies were assessed using the Mixed Methods Appraisal Tool (MMAT). Data extraction focused on incidence, complication rates, risk factors, microbial patterns, and management approaches. Ten studies (n = 14,581 procedures) were included, comprising retrospective cohorts, prospective registries, and surveillance studies. Overall complication rates ranged from 9.4% to 15.9%, with procedure-related mortality of 0.26% to 1.0%. Post-ERCP pancreatitis (PEP) was the most common complication (3.8-17.2%), followed by complications due to infection, including cholangitis (2.4-9.7%) and bloodstream infections (2.24/100 procedures). Microbial studies demonstrated high rates of bile contamination (>86%) with concerning antibiotic resistance patterns, particularly among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.